Uteroglobin is a secretory protein synthesized by most epithelia, including the respiratory tract. It has strong anti-inflammatory properties that appear to be related to the inhibition of phospholipase A2. Recent experimental evidence indicates that uteroglobin has an inhibitory effect on the proliferation and invasion of cancer cells. We investigated the effects of the adenovirusuteroglobin (ad-UG) transduction on the growth of lung cancer cell lines, which did not express the uteroglobin gene. Upon transduction of ad-UG, the rate of cell growth and the ability to produce colonies in soft agar were evaluated. Cell cycle analysis, Western blot for cell cycle-related proteins and annexin V staining for apoptosis were carried out to see if they were associated with the changes in cell growth. All the tested lung cancer cell lines did not express the uteroglobin gene. The growth rates, and colonyforming ability of transformed cells, were significantly inhibited by the induction of uteroglobin gene expression. The DNA histogram showed that the cell fraction of the G2/M phase was increased, and this G2/M phase arrest was related to a decrease of cdk1 and cyclin A. However, a fraction of apoptotic cells were same as the control. From these results, uteroglobin is thought to have an inhibitory effect on the growth of lung cancer cells. This suggests a potential role for uteroglobin in gene therapy for lung cancer.
U
teroglobin is a steroid-inducible, low molecular mass (15.8 kDa) protein, synthesized by the mucosal epithelia of many organs, including those of the thymus, pituitary gland, respiratory and gastrointestinal tracts, and prostate and mammary gland. 1 It is a secretory protein found in blood 2 and urine. 3 Uteroglobin was first discovered in rabbit uterine fluids, as a critical element, having a stimulatory effect on the growth of blastocysts in early pregnancy, so was named blastokinin. 4 Since then, many different names have been ascribed to this protein, based on the tissue or body fluid in which it was detected, or molecules it interacted with, such as retinol and progesterone. For this reason, it is also known as Clara cell secretory protein, lacryglobin, urine protein-1, retinolbinding protein and progesterone-binding protein. 5 This confusing nomenclature led to a consensus for a new generic family name. Secretoglobin has been officially approved as the new generic name referring to the uteroglobin-like molecules with common characteristics, including secretion, small size, alpha-helical and dimeric structure. 6 Uteroglobin is an evolutionarily conserved protein with important physiologic functions. It has potent anti-inflammatory and immunomodulatory abilities by its inhibition of the activity of phospholipase A2. 7, 8 It is also known to inhibit human and rabbit phagocyte chemotaxis and phagocytosis. 9 Mukherjee et al 10 proposed that uteroglobin plays a specific role in masking the antigenicity of developing embryos during implantation. From these results, it is suggested that uteroglobin may protect the developing embryo from immunologic attack on the maternal side, not only by binding to antigenic determinants of embryonic cells, but also by impairing migration of phagocytes, and thus phagocytosis. 11 Normal bronchial epithelia express the UG gene at a high level. However, neither adenocarcinoma, nor cell lines, derived from the lung express the UG gene, or express it at a markedly reduced level. 12 Interestingly, induced expression of UG in some cancer cells results in the loss of their transformed phenotype, for example, invasiveness, adhesiveness to fibronectin and anchorage-independent growth. 13, 14 Saxon et al. reported the introduction of a single copy of the human chromosome 11 that completely suppressed the tumorigenic phenotype of HeLa cells, and it was indicative of the presence of the tumor-suppressor gene(s) on this chromosome. 15 The fact that the location of the UG gene has been mapped to 11q 12.3-13.1 chromosome 16 is very interesting in the light of the result described above. Additionally, the incidence of cancer in UG-knockout mice is known to be extremely high. 5 Taken together, these results suggest that the loss of UG gene expression may be a common characteristic of cancer cells, and UG may act as a tumor suppressor. To confirm this possibility, we investigated the effects of the adenovirusuteroglobin (ad-UG) transduction on the growth of lung cancer cell lines that did not express the uteroglobin gene.
Materials and methods

Cell lines
Eight human lung cancer cell lines (NCI-H358, NCI-H520, NCI-H522, NCI-H2009, NCI-H1299, NCI-H460, NCI-H596 and A549) were obtained from the American Type Culture Collection (Manassas, VA) and the Korean Cell Line Bank (Seoul, Korea).
Preparation of recombinant ad-UG
cDNA of uteroglobin, kindly provided by Shelhamer JH of National Institutes of Health, Bethesda, Maryland, was cloned into BamHI restriction sites of the polylinker of the adenoviral shuttle vector, pACCMVpLpA. The pACCMVpLpA-UG and pJM17 adenoviral packaging plasmids were cotransfected into 293 cells (human renal embryonal cells immortalized by stable transfection with E1 of the adenovirus) using the calcium phosphate precipitation method. The transfected cells were maintained in RPMI with 2% FBS until the onset of the cytopathic effect. The generated adenovirus was purified three times by plaque assays and confirmed by sequencing of the viral DNA and Western blot analysis. A large-scale stock of adenovirus was prepared by the standard CsCl method. Recombinant adenovirus, without any therapeutic gene (ad-null), was used as the control virus in all experiments.
Transduction of lung cancer cell lines with ad-UG Lung cancer cells were transduced with 20 and 100 MOI of ad-UG or ad-null for control virus and incubated for 1 hour with gentle frequent shaking and then incubated with complete media for the experiment. The induction of uteroglobin gene expression was confirmed by Western and Northern blot analyses in cell lysates and media.
Analysis of growth inhibition on lung cancer cell lines
Three lung cancer cell lines (NCI-H460, NCI-H522 and A549) were seeded onto six-well plates (5 Â 10 4 /well). After incubating for 24 hours, cells were transduced with 20 MOI of ad-UG, ad-null or phosphate-buffered saline (PBS). Triplicate wells of each treatment were counted daily for 8 days using a hemocytometer.
Soft-agar clonogenic assay
To assess the effect of uteroglobin gene transfer on in vitro tumorigenicity, soft-agar clonogenic assays were performed. Three lung cancer cell lines (NCI-H460, NCI-H522 and A549) were transduced with 20 MOI of ad-UG, ad-null or PBS. After incubating for 24 hours, cells were isolated, and plated in 0.2% agarose with a 1% agarose underlay (5 Â 10 3 cells/plate). Colonies greater than 125 mm were counted after 4 weeks.
Cell cycle analysis
NCI-H460, NCI-H522 and A549 lung cancer cells were transduced with 20 MOI of ad-UG. After incubating for 48 hours, cell cycle analysis was carried out using CycleTest plus kit protocol (Becton Dickinson, San Jose, CA).
Western blot for cell cycle-related proteins
Western blots for cdk1, cyclins A and B were performed using the ECL Western blotting system and protocol (Amersham). Monoclonal mouse anti-human antibodies for cdk1, cyclin A and cyclin B (Pharmingen, San Diego, CA) were used as primary antibodies.
Annexin V staining for apoptosis
Analyses for apoptosis were carried out using annexin V apoptosis kits (Pharmingen) in three lung cancer cell lines (NCI-H460, NCI-H522 and A549). At 48 and 96 hours after transduction with 20 MOI of ad-UG, cells were isolated by a brief trypsin treatment. The cells were stained with annexin V and PI, according to the manufacturer's instructions, and sorted using a FACS flow cytometer (Becton Dickinson).
Results
Northern blot analyses showed no expression of the uteroglobin gene in lung cancer cell lines
Northern blot analyses were performed to see whether the gene of uteroglobin was expressed in lung cancer cell lines or not. Eight human lung cancer cell lines (NCI-H358, NCI-H520, NCI-H522, NCI-H2009, NCI-H1299, NCI-H460, NCI-H596 and A549) were used. These showed no expression of the uteroglobin gene in any of the tested lung cancer cell lines.
The expression of the uteroglobin gene was induced after transduction of ad-UG Northern blot analyses revealed successful induction of uteroglobin gene expression following transduction of ad-UG in lung cancer cell lines. The amount of induced expression was proportional to the transduced viral burden (Fig 1) . Uteroglobin was also detected in cultured media by Western blot analysis (Fig 2) . This suggests that the transformed cells synthesized uteroglobin and secreted it into the media. Western blot analysis of the brochioloalveolar lavarge in a normal person showed that the expression of uteroglobin gene is constitutively taking place at high level in normal bronchial epithelium. This result contrasted with the Western blot analysis of NCI-H358 showing that the expression of uteroglobin gene was only detected in the transformed cells by ad-UG (Fig 3) .
The growth of transformed cells by ad-UG was significantly inhibited
Cell count was performed daily during the culture for 8 days to evaluate the effect of transduction with ad-UG to cell growth in three lung cancer cell lines (NCI-H460, NCI-H522 and A549). The differences of growth rate between the transformed cells by ad-UG and cells transduced with ad-null or control appeared at 2 days after transduction. Thereafter, the differences of growth rate had been increasing day by day. This revealed that transduction with ad-UG inhibited the growth of transformed cells significantly compared with the cells untransduced or transduced with ad-null in three tested lung cancer cell lines (Fig 4) .
Colony-forming ability in soft agar was suppressed Colony count was performed at 4 weeks after transduction with ad-UG. The colony-forming ability of the transformed cells in soft agar was markedly reduced, by more than 80% (Fig 5) .
G2/M phase arrest was caused by the induction of the uteroglobin gene expression
The induction of uteroglobin gene expression caused G2/ M phase arrest compared to the control. The fraction of G2/M phase in transduced cells of NCI-H460 increased to 51.58% compared to 10.99% in the control and the S phase fraction simultaneously decreased to 15.24% compared to 39.02% in the control (Fig 6) . The results in cells transduced with ad-null were not different from control, showing that the fraction of G2/M phase was 9.33% and S phase fraction was 36.88%. The G2/M phase arrest was also found in A549 and NCI-H522 (Fig 6) .
Western blot for cell cycle-related proteins showed decreased levels of cdk1 and cyclin A Western blot analyses of the cell cycle-related proteins associated with G2/M phase showed decreased levels of cdk1 and cyclin A in three lung cancer cell lines after ad-UG transduction (Fig 7) .
Apoptosis was not induced by the transduction of ad-UG
The transduction of ad-UG did not induce apoptosis at 48 or 96 hours (Fig 8) . There were no differences of apoptotic cell fractions between the transformed cells and control or cells transduced with ad-null. The apoptotic cell fraction in transformed cells of NCI-H460 was 0.04% at 48 hours and 1.02% at 96 hours. It was 1.94% at 48 hours and 0.56% at 96 hours in the control. Similar results were obtained in the cells transduced with ad-null, showing 0.52% at 48 hours and 0.76% at 96 hours. Also in other cell lines (NCI-H522 and A549), apoptosis was not induced by the transduction of ad-UG. Western blot analysis in bronchioloalveolar lavage (BAL) fluids obtaind in a normal person during bronchoscopy showed that uteroglobin was constitutively synthesized and secreted at a high level in normal bronchial epithelium. In NCI-H358 lung cancer cell line, only the transformed cells by ad-UG produced the uteroglobin.
Discussion
Lung cancer is the most common cause of death from cancer in many parts of the world. Despite recent advances in diagnosis and treatment methods, there has been no significant improvement in the survival rate in patients with lung cancer. The poor prognosis, showing less than 15% of 5-year survival rate for this disease, requires new therapeutic methods, such as gene therapy. 17 Gene therapy is the treatment of disease using genetic material as a therapeutic agent. The most common approach to cancer gene therapy is the correction of genetic aberration by the introduction of normal genes. 18 Gene therapy using the wild-type p53 tumor-suppressor gene and adenoviral vector is the most extensively studied in lung cancer. 19 Clinical trials in inoperable lung cancer have consistently revealed that adenovirus-mediated p53 gene therapy can be performed without significant adverse effects, and show potential useful clinical responses. Although it has been shown that gene therapy may be a promising tool in managing patients with inoperable lung cancer, there are many problems to resolve, including developing more effective gene delivery systems, and discovering new therapeutic genes. 20 Uteroglobin is known to be a possible candidate gene, with tumor-suppressor activity. Normal bronchial epithelium produces a large amount of uteroglobin. However, prolonged exposure carcinogens such as tobacco smoke led to reduced uteroglobin expression. On the contrary, the overexpression of uteroglobin made immortalized bronchial epithelial cells delay to have the phenotype of cancer cells in response to carcinogens. 21 This suggests that downregulation of uteroglobin contributes to pulmonary carcinogenesis. The other evidences suggesting that uteroglobin antagonize the neoplastic phenotype have been accumulating. The induction of uteroglobin in a lung cancer cell line caused the reduced invasiveness of cancer cells. 13 Enforced expression by transfection of uteroglobin cDNA in the endometrial adenocarcinoma cell line markedly reduced growth potential and prolonged the time for completion of the cell cycle. 22 The Western blot analyses in our study showed that normal bronchial epithelium synthesized and secreted uteroglobin in high levels, but lung cancer cell lines did not. These coincide well with many previously reported data. After transfer of the uteroglobin gene to lung cancer cell lines, the growth of cancer cells was significantly inhibited and the tumorigenecity, in soft agar, was reduced. These results convincingly support the finding that uteroglobin acts as a tumor suppressor.
Most eukaryotic cells replicate through the cell cycle. Regulation of the cell cycle is critical for the normal development of multicellular organisms. Cdk complexes, composed of a regulatory cyclin subunit and a catalytic cyclin-dependent kinase subunits, regulate the processes in cells, through the cell cycle. 23 To minimize the replication of damaged DNA, and control the order and timing of cell cycle transition, several checkpoints, such as G1/S and G2/M, are present in the cell cycle. 24 The G1/S check point is regulated by cdk4-cyclin D, cdk6-cyclin D, Figure 6 Cell cycle analysis. DNA histogram in NCI-H460 revealed that the induction of uteroglobin gene expression caused G2/M phase arrest. The G2/M phase fraction in transformed cells increased to 51.58% compared to 10.99% in the control and the S phase fraction simultaneously decreased to 15.24% compared to 39.02% in the control. The results of A549 and NCI-H522 were similar to those of NCI-H460.
cdk2-cyclin E and cdk2-cyclin A. The regulation of the G2/M check point is associated with cdk1-cyclin B and cdk1-cyclin A. 25 Checkpoints arrest the cell cycle providing time for repair, and induce transcription of the genes that facilitate repair of damaged DNA. Checkpoint loss causes genomic instability and has been implicated in the evolution of normal cells into cancer cells. 26 Many effectors of tumor-suppressor genes, such as p53, function by controlling the cell cycle. In this study, the induction of uteroglobin expression in lung cancer cells resulted in G2/M phase arrest, which was related to the decreased levels of cdk1 and cyclin A. This suggests that uteroglobin has a functional mechanism similar to other tumor suppressors in the inhibition of cancer cell replication.
Apoptosis is a physiologic mode of cell death, which is different from the accidental cell death process known as necrosis. In response to extensive DNA damage, tumorsuppressor genes, like p53, induce apoptosis to prevent accumulation of multiple mutations that might result in the development of cancer cells. 27 Methods of cancer treatment, such as chemotherapy or radiotherapy, cause damage to DNA in the proliferating cells, resulting in cell death via the induction of apoptosis. 20 Although uteroglobin seems to have many common characteristics of tumor suppressors like p53, it did not induce apoptosis. Further investigation is required to clarify how uteroglobin induces cell death through the arrest of the cell cycle.
Induction of the uteroglobin gene expression have the inhibitory effect on the growth of lung cancer cell lines via the control of cell cycle, leading to the conclusion that the uteroglobin gene is a kind of tumor-suppressor gene, so might be useful in lung cancer gene therapy. Western blots for the cell cycle-related proteins. Western blot analyses for the cell cycle-related proteins associated with the G2/M phase such as cdk1, cyclin A, cyclin B were performed. These showed decreased levels of cdk1 and cyclin A in transduced cells.
